Company Overview - Shenlian Bio is located in Minhang District, Shanghai, established on June 28, 2001, and listed on October 28, 2019. The company specializes in the research, production, and sales of veterinary biological products, with 99.24% of its main business revenue coming from this sector [1][2]. Financial Performance - As of June 30, Shenlian Bio reported a revenue of 122 million yuan for the first half of 2025, a year-on-year decrease of 3.68%. The net profit attributable to the parent company was -12.87 million yuan, showing a year-on-year increase of 62.71% [2]. - The company has cumulatively distributed 158 million yuan in dividends since its A-share listing, with 47.22 million yuan distributed over the past three years [3]. Stock Performance - On September 12, Shenlian Bio's stock price increased by 2.07%, reaching 11.85 yuan per share, with a trading volume of 76.35 million yuan and a turnover rate of 1.61%. The total market capitalization is 4.866 billion yuan [1]. - Year-to-date, the stock price has risen by 116.64%, with a 0.77% increase over the last five trading days, a 10.85% increase over the last 20 days, and a 106.45% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on August 19, where it recorded a net purchase of 16.15 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Shenlian Bio was 9,466, an increase of 6.46% from the previous period. The average circulating shares per person decreased by 6.06% to 43,380 shares [2]. Industry Classification - Shenlian Bio belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically in the animal health industry, and is associated with concepts such as small-cap stocks, pet economy, margin trading, vaccines, and biomedicine [2].

Core Points - The company Shenyuan Biological (688098.SH) reported a revenue of 122 million yuan for the first half of 2025, a year-on-year decrease of 3.68% [1] - The net profit attributable to shareholders was -12.87 million yuan, an improvement from -34.51 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses was -16.80 million yuan, compared to -35.44 million yuan in the previous year [1] - The net cash flow from operating activities was -39.39 million yuan, a significant decline from -0.81 million yuan in the same period last year [1] Financial Performance - In 2024, the company achieved a revenue of 303.41 million yuan, a year-on-year growth of 0.64% [1] - The net profit attributable to shareholders for 2024 was -44.74 million yuan, a decline from a profit of 31.52 million yuan in the previous year [1] - The net profit after deducting non-recurring gains and losses for 2024 was -48.38 million yuan, compared to a profit of 25.07 million yuan in the previous year [1] - The net cash flow from operating activities for 2024 was 89.36 million yuan, up from 3.53 million yuan in the previous year [1] IPO Details - Shenyuan Biological was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2019, with an issuance of 50 million shares at a price of 8.80 yuan per share [1] - The total funds raised during the IPO amounted to 440 million yuan, with a net amount of 400.18 million yuan after deducting issuance costs [2] - The actual net fundraising was 49.83 million yuan less than the originally planned amount of 450 million yuan [2] - The issuance costs for the IPO were 37.57 million yuan, including underwriting fees of 25.47 million yuan [2]

Market Overview - The animal health sector experienced a decline of 0.5% on September 10, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.21, up 2.75% [1] - *ST Lvkang (002868) at 26.42, up 1.62% [1] - Houfeng Holdings (002141) at 4.00, up 0.76% [1] - Major decliners included: - Yongshun Biological (839729) at 10.62, down 3.28% [2] - Shilian Biological (688098) at 11.72, down 1.76% [2] - Huai Sheng Biological (300871) at 22.20, down 1.60% [2] Capital Flow Analysis - The animal health sector saw a net outflow of 81.6 million yuan from institutional investors, while retail investors contributed a net inflow of 53.0 million yuan [2] - The detailed capital flow for key stocks showed: - Repu Biological (300119) had a net inflow of 1.12 million yuan from retail investors [3] - Kexian Biological (688526) saw a net inflow of 14.78 thousand yuan from institutional investors [3] - Hai Li Biological (603718) experienced a significant net outflow of 22.66 million yuan from institutional investors [3]

Core Viewpoint - Shenyuan Biological has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China to produce a dual inactivated vaccine for swine, targeting both Streptococcus suis disease and infectious pleuropneumonia [1] Group 1 - The approved vaccine is specifically for the prevention of infectious pleuropneumonia and Streptococcus suis disease in pigs [1] - The vaccine combines two strains: ZY-2 strain (type 2) and SC strain (type 1) [1] - The approval is in accordance with the Veterinary Drug Management Regulations and the Management Measures for the Approval Numbers of Veterinary Drug Products [1]

证券代码：688098 证券简称：申联生物 公告编号：2025-035 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》《兽药产品批准文号管理办法》等有关规定，经中华 人民共和国农业农村部审查，准予申联生物医药（上海）股份有限公司兰州分 公司生产猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2型ZY-2株+1型SC株）， 并核发兽药产品批准文号批件，具体情况如下： 一、兽药产品批准文号基本情况 1、通用名称：猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2型ZY-2株+1型SC 株） 2、兽药产品批准文号：兽药生字280181168 3、商品名称：传联清 4、有效期：2025年9月3日至2030年9月2日 二、兽药产品及其市场情况 猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2 型 ZY-2 株+1 型 SC 株）用于 预防猪传染性胸膜肺炎和猪链球菌病。猪链球菌病是由猪链球菌引起的细菌性传 染病，主要引起猪的败血症、脑膜炎和关节炎等临床症状；传染性胸膜肺炎是由胸 膜肺炎放线杆菌引起的一种高度接触性呼吸道传染病，其病理特征是纤 ...

申联生物(688098.SH)发布公告，根据《兽药管理条例》《兽药产品批准文号管理办法》等有关规定， 经中华人民共和国农业农村部审查，准予申联生物医药(上海)股份有限公司兰州分公司生产猪链球菌 病、传染性胸膜肺炎二联灭活疫苗(2型ZY-2株+1型SC株)，并核发兽药产品批准文号批件。 该产品的获批及上市将进一步完善公司兽用细菌病防控产品矩阵，产品将在公司已有的细菌灭活疫苗 GMP生产线上生产，将有助于提升产能利用率，为客户提供更全面、高效的疫病防控解决方案。 ...

该产品的获批及上市将进一步完善公司兽用细菌病防控产品矩阵，产品将在公司已有的细菌灭活疫苗 GMP生产线上生产，将有助于提升产能利用率，为客户提供更全面、高效的疫病防控解决方案。 智通财经APP讯，申联生物(688098.SH)发布公告，根据《兽药管理条例》《兽药产品批准文号管理办 法》等有关规定，经中华人民共和国农业农村部审查，准予申联生物医药(上海)股份有限公司兰州分公 司生产猪链球菌病、传染性胸膜肺炎二联灭活疫苗(2型ZY-2株+1型SC株)，并核发兽药产品批准文号批 件。 ...

人民财讯9月8日电，申联生物(688098)9月8日晚间公告，经中华人民共和国农业农村部审查，准予申联 生物医药(上海)股份有限公司兰州分公司生产猪链球菌病、传染性胸膜肺炎二联灭活疫苗(2型ZY-2株+1 型SC株)，并核发兽药产品批准文号批件。 ...

申联生物医药（上海）股份有限公司兰州分公司获批猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2型 ZY - 2株+1型SC株）兽药产品批准文号（兽药生字280181168），有效期至2030年。该疫苗用于预防猪 两种常见传染病，以"精准菌株"等实现"一苗防两病、高效低应激"，对防控意义重大。产品具备上市销 售条件，上市前仅需履行批签发程序。获批将完善公司兽用细菌病防控产品矩阵，提升产能利用率。 ...

Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]